abbv-453
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 17, 2022 (NCT05308654)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06953960 | Phase 1/Phase 2 (Phase 2) | Jul 23, 2025 | AbbVie |
| NCT06291220 | Phase 1 | Aug 9, 2024 | AbbVie |
| NCT05308654 | Phase 1 | May 17, 2022 | AbbVie |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 3 | 3 | 2 | 2022 |
1 organizations
Page 1 / 1